A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs Clobetasol (Primary)
- Indications Ocular inflammation; Ocular pain; Postoperative inflammation; Postoperative pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Formosa Pharmaceuticals
- 04 Nov 2024 Results published in the Formosa Pharmaceuticals Media Release
- 16 Oct 2024 According to an Eyenovia media release, results from this trial will be presented at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago.
- 02 Jul 2024 According to a NovaBay Pharmaceuticals media release, Eyenovia acquired the U.S. commercial rights to Clobetasol from Formosa Pharmaceuticals in August 2023.